Integrating GLP-1 Management into the Medicare Annual Wellness Visit (AWV)

Editor’s Note: The Medicare GLP-1 Bridge Program and the subsequent BALANCE Model are evolving federal initiatives. This information is subject to change based on upcoming CMS guidance and federal rule-making.

Key Takeaways:

• Leverage the AWV to document BMI and cardiovascular comorbidities, serving as the formal trigger for coverage under the Medicare GLP-1 Bridge.
• Prioritize "resistance training as medicine" and high protein intake to preserve lean mass during rapid GLP-1-induced weight loss in older adults.
• De-prescribe weight-promoting agents and monitor drugs sensitive to delayed gastric emptying.

The landscape of obesity management for the Medicare population is undergoing a seismic shift. With the recent launch of the Medicare GLP-1 Bridge and the upcoming BALANCE Model, clinicians now have the regulatory and financial framework to integrate high-efficacy glucagon-like peptide-1 receptor agonists (GLP-1s) into the care of older adults.¹

The Annual Wellness Visit as a strategic pivot point

The Annual Wellness Visit is designed for health risk assessment and the creation of a personalized prevention plan. Under Centers for Medicare and Medicaid Services (CMS) guidelines, the AWV mandates the measurement of height, weight, and Body Mass Index (BMI).²

Historically, this often led to a simple "counseling" note. In 2026, however, this data point should trigger a comprehensive obesity management pathway.¹

By integrating GLP-1 management into the AWV, clinicians can align weight loss goals with the "preventive" nature of the visit. The Bridge program has expanded to allow for the coverage of GLP-1s for weight management, whereas previously it had to be tied to reducing the risk of major adverse cardiovascular events.¹

Navigating the current regulatory landscape

As of July 1, 2026, the Medicare GLP-1 Bridge demonstration has simplified access for eligible beneficiaries. This program provides a pathway for Part D coverage of GLP-1s for obesity when paired with specific clinical criteria, such as a BMI ≥30 or ≥27 with a qualifying comorbidity like pre-diabetes or hypertension.¹

Clinicians should use the AWV to verify these criteria and initiate the required prior authorization. The 2026 "Bridge" is a precursor to the BALANCE Model, set to begin in 2027, which will further institutionalize obesity pharmacotherapy within the Medicare framework. Understanding these timelines is crucial; a patient seen for an AWV in mid-2026 can be "bridged" into long-term coverage, ensuring continuity of care during the critical titration phase.¹

Clinical nuances: Sarcopenia and the older adult

Treating obesity in the Medicare population requires a delicate balance between weight loss and the preservation of functional status. A significant concern with rapid weight loss via GLP-1s in seniors is the risk of accelerated sarcopenia.³

Recent data indicate that while GLP-1s are highly effective, a substantial amount of the total weight lost may come from lean body mass. In patients aged 65 and older, this loss of muscle can exacerbate frailty and increase fall risk.³

To mitigate this, the AWV should be used to:^3,4

• Establish a baseline – Use handgrip strength or the SARC-F screen during the AWV to assess baseline muscle health.
• Prescribe resistance training – Pharmacotherapy should never be prescribed in a vacuum. Clinicians should mandate a high-protein diet and resistance exercise as part of the AWV’s Personalized Prevention Plan.
• Monitor titration – Older adults often experience more pronounced gastrointestinal side effects. A "low and slow" titration schedule is recommended to maintain caloric intake and prevent rapid, debilitating weight loss.

Managing other medications

The mandatory medication review within the AWV offers a critical window for polypharmacy optimization in the context of GLP-1 therapy. For older patients, the introduction of a GLP-1 is not merely an addition to the regimen; it is a catalyst for deprescribing.^2,3

Clinicians should prioritize the identification and titration of "weight-promoting" medications – such as certain beta-blockers, corticosteroids, and antipsychotics – that may antagonize the therapeutic goals of GLP-1 treatment.

Furthermore, the pharmacokinetics of GLP-1 RAs require heightened vigilance regarding delayed gastric emptying. While this mechanism contributes to satiety, it can significantly alter the absorption profiles of medications with narrow therapeutic indices.³

Finally, as weight loss progresses, the AWV should serve as a checkpoint for the aggressive de-escalation of antihypertensive and glucose-lowering therapies. Rapid weight loss can lead to orthostatic hypotension or hypoglycemia in patients concurrently using sulfonylureas or insulin. By proactively adjusting these dosages, clinicians can prevent the adverse events that often lead to medication non-adherence or emergency department visits in the geriatric population.^2,3

A new standard of care

Integrating GLP-1 management into the Medicare AWV is no longer just a clinical option. It is becoming a standard of care for the comprehensive management of aging patients.¹

By utilizing the new Medicare Bridge coverage, clinicians can significantly improve the cardiovascular and metabolic outcomes of their older patients. The AWV serves as the foundation – a yearly opportunity to pivot from passive monitoring to active, life-extending obesity intervention.¹